Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMM-6-415 · 1 trial · 4 indications
Number of participants with adverse events
Number of participants with dose-limiting toxicities
Selection of candidate RP2D to take forward into Ph2a
Cmax
Tmax
AUC0-t
Surrogate PD Biomarker Assay, pERK
The proportion of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR), based on RECIST 1.1 criteria
| Arm | Type | Description |
|---|---|---|
| IMM-6-415 | EXPERIMENTAL | Dose Escalation and Dose Expansion |
| Name | Type | Description |
|---|---|---|
| IMM-6-415 | DRUG | Twice daily, oral tablet administered in 21-day cycles until treatment discontinuation criteria are met. |
Inclusion Criteria: * Age ≥18 years * Life expectancy \>16 weeks * Part 1: Histologically or cytologically confirmed diagnosis of a locally advanced unresectable or metastatic solid tumor malignancy harboring RAS (NRAS, KRAS, or HRAS)- or RAF- (ARAF, BRAF, RAF1) activating mutations, as documented ...
IMM-6-415 is an investigational small molecule being studied for the treatment of advanced solid tumors, including pancreas adenocarcinoma, non-small cell lung cancer, and cutaneous malignant melanoma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
IMM-6-415 is designed to target tumors with RAS/RAF mutations, as indicated by the clinical trial title. It is a small molecule therapeutic being developed for cancers that harbor these genetic alterations, which are common in several solid tumor types.
IMM-6-415 is being developed by Immuneering Corporation, a biopharmaceutical company. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with advanced solid tumors.
IMM-6-415 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory agencies. The Phase 1 trial has been completed, and the drug remains under investigation for safety and dosing.
IMM-6-415 has been studied in one clinical trial with the identifier NCT06208124, titled 'A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors.' This Phase 1 trial enrolled 30 participants with advanced solid tumors and was completed in the United States.
IMM-6-415 is a unique investigational drug developed by Immuneering Corporation. No alternative names for this drug have been reported in the available clinical trial information. It is being studied specifically for RAS/RAF mutant solid tumors.